Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will make it her policy to make an assessment of the potential impact of any proposed amendments to Part IX of the Drug Tariff on (a) patients with continence care needs, (b) continence care services, (c) the range of continence devices available to clinicians and patients and (d) new product development and innovation in medical devices in the continence sector.

Part IX will remain a list of devices available to be prescribed in the community, via the FP10 prescription route. The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on were intended to increase meaningful choice, not to decrease the choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers, which can support small and medium sized businesses in entering the market.

The consultation response on the proposed amendments to Part IX is expected to be released in May 2024, which will outline the Government’s response. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and National Health Service organisations. We are aware that there are some very good devices in use, relied upon by clinicians and patients.